Summary. Methionine-enkephalin and leucineenkephalin, administered into the lateral ventricle of intact rats, increased the accumulation of DOPA by a naloxone-sensitive mechanism in different brain regions after inhibition of the aromatic L-amino acid decarboxylase. Because of the rapid enzymatic degradation of both enkephalins large doses (500 pg) were required to enhance brain catecholamine synthesis. The two enzyme resistant enkephalin analogues D-Ala 2-methionine enkephalin amide (DALA (4-256 pg) and FK 33-824 (0.003 -1 pg) also increased the synthesis of DOPA, dose-dependently and by naloxone-sensitive mechanisms, but at much lower dosage level. The enkephalins markedly enhanced the brain tyrosine concentration but this effect was not antagonized by naloxone, probably because the enzymatic cleavage releases tyrosine from the administered peptides. In contrast, neither DALA nor FK 33-824 increased the brain tyrosine concentration. The formation of 5-HTP and the brain tryptophan concentration were also increased by the enkephalins, although these effects were not blocked by naloxone. The enkephalin analogues, however, enhanced the formation of 5-HTP and the brain tryptophan concentration by naloxonesensitive mechanisms. All four peptides accelerated the disappearance of dopamine, noradrenaline and 5-hydroxytryptamine after inhibition of monoamine synthesis. The results suggest that endogenous enkephalins, through the activation of opiate receptors, are involved in the short-term regulation of central monoaminergic systems.
Introduction
The enkephalins, methionine (MetS)-enkephalin (HTyr-Gly-Gly-Phe-Met-OH) and leucine (LeuS)-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH), are naturally occurring peptides with morphine-like pharmacological properties which have recently been isolated and characterized from mammalian brain (Hughes et al., 1975) . Both pentapeptides are widely though unevently distributed in the central nervous system (Hong et al., 1977; Hughes et al., 1977) , and their similar regional distributions closely parallel that of the opiate receptor (for a review see Snyder and Simantov, 1977) . Moreover, they are subcellularly located in synaptosomal and microsomal fractions (Osborne et al., 1978a) and their in vitro release from brain slices and synaptosomal preparations by a calcium-dependent process have been reported (Henderson et al., 1978; Iversen et al., 1978; Osborne et al., 1978b) . All these observations suggest that the enkephalins play a neurotransmitter/ neuromodulator role in the central nervous system (for a review see Frederickson, 1977) .
It is well established that morphine and other narcotic analgesics modulate the brain dopamine turnover by a naloxone-sensitive mechanism (Kuschinsky, 1976) . We have recently reported (Garcia-Sevilla et al., 1978) that the acute administration of the opiatereceptor agonists, morphine and fl-endorphin, increase the synthesis of dopamine and serotonin in the brain of intact rats, while the opiate-receptor antagonists, naloxone and naltrexone have opposite effects. These data suggest that the opiate receptors and their en-Naunyn-Schmiedeberg's Arch. PharmacoI. 310 (i980) dogenous ligands are involved in the short-term regulation of both neurotransmitters.
Consequently, the present investigation was carried out to assess the effects of the enkephalins on brain monoamine turnover. Because of the rapid degradation of both Met 5-and LeuS-enkephalins by brain peptidases (Meek et al., 1977; Dupont et at., 1977) , the effects of two metabolically stable synthetic analogues, D-Ala 2-methionine enkephalin amide (Pert et al., 1976) and the FK 33-824 compound (Roemer et al., 1977) , were also studied.
Materials and Methods
Animals. Male Sprague-Dawley rats weighing 200-250 g (Anticimex, Stockholm, Sweden) were used. The animals received a standard diet with water freeIy available and were housed at 24~ under a 12 h lightdark cycle.
Drugs. 3-Hydroxybenzylhydrazine HCI (NSD 1015, synthesized in this institute by Dr. P. Lindberg) and N-(BL-seryl)-NZ-(2,3,4 -trihydroxybenzyl)hydrazine (Ro4-4602 or benserazide, F. Hoffmann-La Roche Co., Basle, Switzerland) were dissolved in 0.9 % w/v NaC1 solution (saIine) and injected intraperitoneally (i. p.) Met 5-enkephalin, LeuS-enkephalin and D-Ala2-methionine enkephalin amide (DALA) (purchased from Serva Feinbiochemica, Heidelberg, FRG) and D-Ala 2, MePhe 4, Met(O) 5-ol-enkephalin (FK 33-824) (gift from Dr. Roemer, Sandoz Ltd., Basle, Switzerland) were dissolved in saline and injected intracerebroventricularly (i. c~v.). Naloxone (gift from Dr. Ferster, Endo Laboratories, Inc.) was dissolved in saline and injected i.p. or s. c. The time and dose schedules for injections are given in the Results section. Control rats always received the same number of injections of saline at the same time intervals as the experimental animals.
Implantation of Intracerebroventricular Cannulae. A polyethylene cannula was permanently implanted into each lateral ventricle as described in detail previously (Garcia-Sevilla et al., 1978) . The experiments were performed 2 days after the operation when the gross behaviour of the animals was normal. The proper position of the cannulae was checked at autopsy.
Synthesis of Brain Monoamines.
The in-vivo activity of tyrosine and tryptophan hydroxylase, rate-limiting enzymes in the synthesis of monoamines, were studied by measuring the accumulation of 3,4-dihydroxyphenylalanine (DOPA) and 5-hydroxytryptophan (5-HTP) within 30 rain after inhibition of the aromatic L-amino acid decarboxy~ase by a supramaximai dose of NSD 1015 (100mg/kg) (Carlsson et al., I972) . The enkephalins (500 gg), DALA (4-256 gg) and FK 33-824 (3 ng-1 ~g) were injected i. c.v. ; half of the dose was given into the right lateral ventricle followed within 1 min by the same amount into the left lateral ventricle (10 gl of peptide solution followed by 5 gl of saline into each ventricle). Control rats received 15 ~1 of saline into each ventricle. The aim of these experiments was to study the effects of enkephalins and analogues on the rate of formation of noradrenaline, dopamine and 5-hydroxytryptamine.
Utilization of Brain Monoamines. The utilization of noradrenaline, dopamine and 5-hydroxytryptamine (5-HT) was determined by the disappearance of the amines after inhibition of synthesis by another inhibitor of the aromatic e-amino acid decarboxylase, benserazide (800 mg/kg, i. p.) (And6n et al., 1967) . Immediately after the administration of this inhibitor, the enkephalins (500 gg), DALA (50 gg) or FK 33-824 (1 l~g) were injected i.c.v, followed after 25min by a second dose representing 40 % of the first one (see above). Control animals received the same voIume of satiric. The rats were decapitated 60min after the injection of benserazide. This experiment was designed to investigate the influence ofenkephatins and analogues on the rate of disappearance of monoamines after inhibition of synthesis. This disappearance rate is largely dependent on the rate of nerve impulse flow (And~n et al., 1969) .
Dissection of the Brain. After decapitation of the rats the brains were quickly removed and dissected on an ice-cold plate into the following parts: (1) Iimbic forebrain containing certain dopamine-rich structures e.g. the olfactory tubercle, nucleus accumbens (medial part), nucleus amygdaloideus centralis and part of the paleocortex, (2) corpus striatum, (3) the remainder of the hemispheres including hippocampus (referred to as hemispheres), (4) diencephalon and (5) lower brain stem. Dopamine is the predominating catecholamine in parts (1) and (2) and noradrenaline in parts (3), (4) and (5). For details of dissection see Carlsson and Lindqvist (1973) . The dissected brain parts were immediately frozen on dry ice and the parts of two brains were pooled, weighed and stored at -80 ~ C. In the experiments of utilization of brain monoamines, whole brains were used for assay.
Biochemical Assays. After thawing, the pooled brain parts or the whole brains were homogenized in 10ml of 0.4N perchloric acid containing 5rag sodium metabisulphite and 20mg EDTA (final volume 10.3ml). The homogenates were centrifuged at about t0,000g for 10min at 0~ and the supernatant purified on a strong cation exchange column (Dowex 50 W, X-4) Atack and Magnusson, 1978) . The following spectrophotofluorimetric analysis were performed: tyrosine (Waalkes and Udenfriend, 1957) , DOPA , tryptophan (B~dard et al., 1972) , 5-HTP (Atack and Lindqvist, 1973) , dopamine (Atack, 1973) , noradrenaline (Bertler et al., 1958; Kehr et al., 1976) , 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) (Atack and Lindqvist, 1973) .
Statistics.
One-way analysis of variance followed by t-test, using the within groups variance, was used. The level of significance was chosen as P = 0.05.
Results

Effects of the Enkephalins and their Synthetic Analogues DALA and FK 33-824 on Tyrosine Hydroxylase Activity in vivo
The i.c.v, injection of either Met 5-and Leu 5-enkephalin (500 ~g/rat) enhanced the formation of DOPA in the brain of rats treated with the aromatic Lamino acid decarboxylase inhibitoL NSD 1015 (Table 1 ). In the various brain regions, however, the increases induced by were significantly higher than those of MetS-enkephalin (10-35 %). As expected, naloxone (10 mg/kg), a pure opiate receptor antagonist, blocked these increases in all brain regions, except in the lower brain stem for Met5-enkephalin (Table 1 ). The two enzyme resistant enkephalin analogues DALA and FK 33-824 caused the same effect but with the expected differences in potency. Thus, the i. c. v. administration of DALA (4-256 ~tg/rat) and FK 33-824 (0.003-I I~g/rat) significantly increased the synthesis of DOPA in a dosedependent manner and by a naloxone-sensitive mechanism (Figs. 1 and 2). As the figures show, the log dose-response curves for the two enkephalin analogues Table 1 . Effects of enkephalins on DOPA formation in rat brain regions. The enkephalins (500 pg/rat) were injected intracerebroventricularty (i. c. v.) 10 min before NSD 1015 (3-hydroxybenzylhydrazine; 100 mg/kg i.p.) and the rats were killed after another 30 min. Control rats received i. c. v. the same volume of saline 10 min before the NSD 1015. Naloxone (10 mg/kg) was given either s. Leu 5-vs Met 5-enkephalin P < 0.05 P < 0.001 P < 0.05 NS P < 0.025
Statistical significances were calculated according to one way analysis of variance followed by t-test. Differs from control: * P < 0.05; 9 * P< 0.01; *** P< 0.001
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'~176 o~ ,oo I. , The four opioid peptides differed largely in potency, FK 33-824 being about 100-1,000 times more potent Table2. Effects of enkephalins and synthetic analogues t>Ala2-methionine enkephalin amide (DALA) and D-AIa z, MePhe 4, Met(O)S-olenkephalin (FK 33-824) on the concentration of tyrosine in rat brain regions. The enkephalins (500 lag/rat) and the synthetic analogues DALA (125 lag/rat) and FK 33-824 (1 gg/rat) were injected intracerebroventricuIarly (i.c.v.) 10min before NSD 1015 (3-hydroxybenzylhydrazine; 100 mg/kg i. p.) and the rats were killed after another 30 rain. Control rats received i. c. v, the same volume of saline t0 rain before the NSD 1015. Nal oxone (10 mg/kg) was given either s. c. 30 min before MetS-enkephalin or i.p. 60 rain before LeuS-enkephalin Met s-vs Leu senkephalin P < 0.001 NS P < 0.001 P < 0.001 P < 0.005
Statistical significances were calculated according to one way analysis of variance followed by t-test. Differs from control: * P < 0.05; 9 ** P < 0.001 than DALA in the various brain regions, and the latter about 100 times more potent than the enkephalins. In the limbic forebrain, a dopamine-rich area, 3 ng/rat of the FK 33-824 compound was the minimal effective dose which significantly increased the formation of DOPA after decarboxylase inhibition (43~; P< 0.001) (Fig. 2) . This enkephalin analogue also proved active in increasing DOPA accumulation (22 ~; P < 0.05) in the limbic forebrain after systemic administration (5 mg/kg; s.c.). Both Met s-and Leu 5-enkephalin markedly increased the brain tyrosine concentrations in all brain regions, except in the corpus striatum where the effect was modest (Table 2 ). In the various brain regions the increases induced by Met senkephalin (85-140 ~) were significantly higher than those of LeuS-enkephalin (50-70 ~o). For both peptides this effect was not antagonized by naloxone (10mg/kg). In contrast to the enkephalins, neither DALA (125 lag/rat) nor FK 33-824 (1 gg/rat) increased the brain tyrosine concentration (Table 2) .
Effects of the Enkephalins and their Synthetic Analogues DALA and FK 33-824 on Tryptophan Hydroxylase Activity in vivo
The i.c.v, injection of Met 5-or LeuS-enkephalin (500 gg/rat) enhances 5-HTP formation in several brain parts of rats treated with NSD 1015 (Table 3) . Leu 5-enkephalin was ineffective in the limbic forebrain, corpus striatum and hemispheres, whereas Met senkephalin induced a small but significant increase (10-15 ~) in the two last mentioned brain regions. In the diencephalon and in the lower brain stem the enkephalins consistently increased the synthesis of 5-HTP and for the both peptides this effect was of the same magnitude (20-30~). Unexpectedly, the increases in 5-HTP formation induced by Met 5-and LeuS-enkephalin were not blocked by naloxone (10 mg/kg) ( Table 3) . The DALA analogue (125gg/rat) increased the formation of 5-HTP in the diencephalon and in the lower brain stem to about the same extent (20 ~), as did the enkephalins, but had a stronger effect than the natural enkephalins in the limbic forebrain, corpus striatum and hemispheres (20 -60 ~o) (Table 4) . Lower doses of DALA were ineffective in enhancing 5-HTP accumulation after decarboxylase inhibition (data not shown). The FK 33-824 compound moderately increased the synthesis of 5-HTP in various brain regions (10--25 ~o, Table 4 ). In contrast to the enkephalins the increases in 5-HTP formation induced by the synthetic analogues were completely blocked by the previous administration of naloxone (10 mg/kg) ( Table 4) . Table 5 shows the effects of the enkephalins and the synthetic analogues on tryptophan concentrations in the various rat brain regions. The increases induced by Mer and LeuS-enkephalin (15-50~) were at most partially blocked by naloxone (10mg/kg), whereas those induced by DALA (20 ~) were blocked by the opiate receptor antagonist. The FK 33-824 compound did not increase the tryptophan concentrations in any brain region, except in the limbic forebrain (17~o; P < 0.05) ( Table 5) . Table 3 . Effects of enkephalins on 5-hydroxytryptophan (5-HTP) formation in rat brain regions. The enkephalins (500 lag/rat) were injected intracerebroventricularly (i.c.v.) 10 min before NSD 1015 (3-hydroxybenzylhydrazine; /00 mg/kg i.p.) and the rats were killed after another 30 rain. Control rats received i. c. v. the same voiume of saline 10 rain before the NSD 1015. Naloxone (10 mg/kg) was given either s.c. and 30 rain before MetS-enkephalin or i.p. and 60min before LeuS-enkephalin Statistical significances were calculated according to one way analysis of variance followed by t-test. Differs from control: * P< 0.05; 9 * P < 0.01 ; *** P < 0.001
Effects of the Enkephalins and their Synthetic Analogues DALA and FK 33-824 on the Utilization of Dopamine, Noradrenaline and 5-HT
After inhibition of monoamine synthesis by benserazide, both Met< and Leu<enkephalin significantly accelerated the disappearance of dopamine and had a similar though small and statistically nonsignificant effect on noradrenaline. Leu<enkephalin increased the utilization of dopamine to a larger extent than did Met5-enkephalin (34~ vs. 18 ~; P < 0.025). For both opioid peptides the significantly accelerated disappearance of 5-HT was accompanied by simultaneous increases in 5-HIAA brain levels (Table6). Similar results were obtained with the synthetic analogues DALA and FK 33-824 but at much lower dosage level. In contrast to the enkephalins these analogues significantly accelerated the disappearance of noradrenaline. The FK 33-824 compound did not accelerate the utilization of 5-HT but increased the 5-HIAA brain levels ( Table 6 ).
Behaviour of the Animals
Both the enkephalins (500 Ixg/rat) and their synthetic analogues DALA (4-250txg/rat) and FK 33-824 (0.003 -1 ~tg/rat) induced a very similar morphine-like behavioural pattern, but with marked differences in potency for the different compounds. The i.c.v, injections of these peptides caused a loss of both the corneal and the eyelid reflexes, exophtalmus, analgesia (loss of tail-pinch reflex), salivation, catalepsy (akinesia) and cata{onia (muscular hypertonus). They also caused acute episodes of wet-dog shaking behaviour Differs from the respective control: * P < 0.05; ** P < 0.01; *** P < 0.001 (one way analysis of variance followed by t-test) and especially after large doses of DALA (125 I~g/rat) rotational behaviour (barrel rotation). For the two synthetic analogues this behavioural pattern was longlasting (more than 40 rain). As already mentioned the differences in potency were very striking; even a dose as low as 3 ng/rat of the FK 33-824 compound clearly induced a loss of the corneal reflex, exophtalmus, piloerection and cataleptic postures in some of the rats. It should be mentioned that FK 33-824, the most potent opioid peptide studied, caused the same behavioural pattern also after systemic administration (5mg/kg; s.c.). Naloxone (lmg/kg; s.c.) was able not only to prevent but also to reverse within 2 rain all the fully developed behavioural manifestations induced by a large dose of DALA (250 gg/rat; i.c.v.).
Discussion
The intracerebroventricular administration of Met 5-and Leu<enkephalin or their more stable analogues DALA and FK 33-824 stimulated the synthesis of dopamine, noradrenaline and 5-hydroxytryptamine by naloxone-sensitive mechanisms, and their utilization after inhibition of synthesis. Therefore, it is tempting to conclude that endogenous enkephalins, through the activation of opiate receptors, are involved in the shortterm regulation of central monoaminergic systems. Further evidence is provided by the fact that the acute administration of the pure opiate receptor antagonists, naloxone and naltrexone, decreased the brain dopamine and 5-hydroxytryptamine synthesis (cf. GarciaSevilla et al., 1978) . The enkephalins and their synthetic analogues DALA and FK 33-824 enhanced the formation of DOPA by a naloxone-sensitive mechanism, both in the dopamine-and noradrenaline-rich areas of the brain. These results confirm and extend recent findings showing a naloxone-sensitive increase in the synthesis of dopamine in the caudate nucleus after the i.c.v, in-jection of DALA (Biggio et al., 1978) . As expected, the opioid peptides showed marked differences in potency in stimulating brain catecholamine synthesis. It has been reported that the breakdown of both Met 5-and Leu 5-enkephalin by brain peptidases is entremely rapid (Meek et al., 1977; Dupont et al., 1977) , which, in turn, may account for the relatively large doses (500 lag/rat) needed for behavioural and biochemical effects. However, the low potency of the enkephalins can be increased after chemical manipulation of the Met 5-enkephalin molecule. The replacement of glycine 2 by I> alanine and amidation of the C-terminal carboxyl group (DALA), or the replacement of glycine z by Dalanine together with N-methylation of the phenylalanine residue and the transformation of the methionine to methioninol sulphoxide , protect against peptidase activity (Pert et al., 1976; Roemer et al., 1977) and the resulting enkephalin analogues show a considerable increase in potency. Thus, the analogues DALA and FK 33-824 were 102-105 times more potent than the enkephalins in stimulating tyrosine hydroxylase activity in vivo. This neurochemical effect of the enkephalins was particularly striking in the dopamine-predominant parts of the brain, i.e. the limbic forebrain and the corpus striatum, where the doses of FK 33-824 required to increase the formation of DOPA were in the nanogram range (see Fig. 2 ). This extremely potent enkephalin analogue proved active also after systemic administration in agreement with published data (Roemer et al., 1977) , indicating that the modification of the MetS-enkephalin molecule also enables penetration through the blood-brain barrier. Both Met 5-and LeuS-enkephalin markedly increased the brain tyrosine concentration but this effect was not antagonized by naloxone, indicating that opiate receptors were not involved. It is unlikely that such an unspecific effect accounts for the specific increases (i. e. blocked by naloxone) in catecholamine synthesis induced by the enkephalins. In fact, it has been reported that the first step in the enzymatic breakdown of enkephalins is the split of the Tyr-Gly amide bond, releasing free tyrosine (Meek et al., 1977; Dupont et al., 1977) . The tyrosine released from the administered peptide might well explain the marked increases in brain tyrosine observed here and by others (Calderini et al., 1978) and the lack of antagonism by naloxone. In support of this possibility it was found that the two enzyme resistant analogues DALA and FK 33-824 did not increase the brain tyrosine concentration (see Table 2 ). In the various brain regions, the increases in tyrosine concentrations induced by MetS-enkephalin (85 -140 ~) were higher than those of LeuS-enkephalin (50-70 ~ suggesting that the former peptide was more rapidly inactivated by enzymatic cleavage, which may explain its lower activity on DOPA formation (see Tables 1 and 2) .
It has recently been reported that MetS-enkephalin decreases both the brain dopamine and noradrenaline turnover, while the synthetic analogue DALA increases that of dopamine without affecting noradrenaline turnover (Calderini et al., 1978) . As discussed by these authors, however, the decrease in the catecholamine turnover induced by MetS-enkephalin might be an artifact involving an isotopic dilution effect, since the measurement of the changes in turnover were based on the apparent conversion of 3H-tyrosine into dopamine and noradrenaline during a simultaneous increase in brain tyrosine concentration induced by the peptide. When this difficulty was circumvented by measuring the accumulation of DOPA after decarboxylase inhibition, we found that both MetS-enkephalin and DALA increased catecholamine synthesis and metabolism independently of the brain tyrosine concentration.
The enkephalins also enhanced the formation of 5-HTP and the brain tryptophan concentration, but these effects were at most only partially blocked by naloxone. Therefore, the possibility that the simultaneous increases in tryptophan concentration may secondarily affect the synthesis of 5-HT has to be considered. However: we cannot discard a stimulating action of the enkephalins on 5-HT neurons as indicated by the enhanced depletion after inhibition of synthesis by benserazide. In contrast to the enkephatins, the DALA analogue increased the accumulation of 5-HTP and the concentration of cerebral tryptophan by naloxonesensitive mechanisms. As the utilization of 5-HT was also accelerated, a specific effect on serotoninergic neurons seems to be involved. However, a comparatively large dose of DALA (125 lag/rat) was needed to enhance brain 5-HT turnover. Since DALA stimulated the formation of DOPA at a much lower dosage level (4 lag/rat) a more selective action of the enkephalins on catecholaminergic neurons can be suggested.
The gross behavioural profiles induced by the enkephalins and synthetic analogues showed a close similarity with those induced by morphine and other opiated (Garcia-Sevilla et al., 1978; Browne et al., 1979) , suggesting the involvement of common mechanisms. However, whether or not this behavioural pattern is correlated with the enkephalins-induced changes in brain monoamines remains to be elucidated.
Finally, the neurochemical results do not give any indication where the opiate receptors, responsible for the increased monoamine synthesis, are situated. It has been reported, however, that the naloxone-sensitive stimulating effect of DALA on DOPA formation in the caudate nucleus persists after destruction of striatal dopamine receptors with kainic acid, suggesting that the opiate receptors which mediate this effect are located on dopaminergic nerve terminals (Biggio et al., 1978) . It is known that presynaptic opiate receptors are involved in the regulation of transmitter release in the central nervous system. In fact, the existence of presynaptic inhibitory opiate receptors both in dopaminergic (Loh et al., 1976) and noradrenergic (Taube et al., 1977 ) nerve terminals have been described. Therefore, it is possible that the observed increased monoamine synthesis induced by the enkephalins might be the compensatory mechanism for a decreased release of dopamine and noradrenaline induced by the opioid peptides.
